It has therefore become a critical therapeutic target in COVID-19, and a soluble form of ACE2, which binds to the spike (S) domain of SARS-CoV-2, prevents the virus from binding to cell membrane-bound ACE2 and infecting the cell, at least in vitro13–15. This evidence concerns the gene ACE2 and COVID-19.